<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00574912</url>
  </required_header>
  <id_info>
    <org_study_id>IRB#060887-Lantus Glargine</org_study_id>
    <secondary_id>VUMC 32787</secondary_id>
    <nct_id>NCT00574912</nct_id>
  </id_info>
  <brief_title>Characteristics of Glargine in Type 2 Diabetics</brief_title>
  <official_title>A Comparison of PK/PD Dose Response Characteristics of Glargine in Type 2 Diabetics</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanderbilt University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Vanderbilt University Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is to determine the dose response relationship of insulin glargine in type 2
      diabetes over a 24-hour period and measuring the differences in glucose production among the
      differing doses of glargine.

      Hypothesis: Differing doses of insulin glargine over a 24-hour period in type 2 diabetes will
      show differing effects on endogenous glucose production, glucose disposal and carbohydrate
      and lipid flux.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The incidence of type 2 DM is increasing worldwide at an alarming rate. Unfortunately, the
      number of individuals with glycemic control at or below the American Diabetes Association
      goal of 7% has dropped. In fact, the number of patients with their important cardiometabolic
      risk factors of glucose, lipids and blood pressure at goal is only 7%. One of the reasons for
      this lack of metabolic control in type 2 DM is the continued relative underutilization of
      insulin. Diabetes is an insulin deficient state and requires appropriate physiologic
      replacement of insulin. Physiologic replacement of insulin requires a basal component to
      restrain overnight endogenous glucose production, lipolysis and proteolysis. The other
      component involves prandial insulin to regulate post prandial glucose levels. Recently,
      insulin glargine was introduced as a once-a-day peakless basal insulin. This form of basal
      insulin reproduces the normal constitutive physiologic release of insulin from the pancreas.
      Insulin glargine represents a breakthrough in treatment as the previous available &quot;basal
      insulins&quot; either produced peaks of activity (which are disadvantageous as this results in
      hypoglycemia) or do not last 24 hrs which results in post absorbative hyperglycemia. Despite
      the undoubted advantages of insulin glargine, there remains a lack of information regarding
      some aspects of glargine action. The study objectives are: 1) to determine the
      pharmacokinetic and pharmacodynamic dose response relationship of insulin glargine in Type 2
      DM; 2) partition the dose response relationship of insulin glargine on endogenous glucose
      production and glucose uptake in Type 2 DM; and 3) to determine if the pharmacokinetic and
      pharmacodynamics of insulin glargine are consistent over a wide range of doses.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2007</start_date>
  <completion_date type="Actual">January 2010</completion_date>
  <primary_completion_date type="Actual">September 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Glucose Infusion Rate</measure>
    <time_frame>24 hours</time_frame>
    <description>measuring the changes in glucose infusion rate during the 24 hour experimental period.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>Placebo then Insulin Glargine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placebo: administer single dose of Placebo subcutaneously (SC) with blood glucose monitoring over 24 hours.
Then Insulin Glargine SQ 8 weeks later, in increasing doses (0.5, 1.0, 1.5, 2.0 u/kg body wt.) with blood glucose monitoring monitoring over a 24 hour period. Each dose is separated by 8 weeks (5 separate study visits)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>single dose of Placebo injected s/c at 8am and monitor blood glucose over 24 hours</description>
    <arm_group_label>Placebo then Insulin Glargine</arm_group_label>
    <other_name>Lantus</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin Glargine 0.5 u/kg body wt SC</intervention_name>
    <description>8 weeks later, a differing dose (0.5, 1.0, 1.5, 2.0 u/kg body wt.) of Insulin Glargine and monitoring over a 24 hour period each separated by 8 weeks (5 separate study visits)</description>
    <arm_group_label>Placebo then Insulin Glargine</arm_group_label>
    <other_name>Lantus</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin Glargine 1.0 u/kg body wt SC</intervention_name>
    <arm_group_label>Placebo then Insulin Glargine</arm_group_label>
    <other_name>Lantus</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin Glargine 1.5 u/kg body wt SC</intervention_name>
    <arm_group_label>Placebo then Insulin Glargine</arm_group_label>
    <other_name>Lantus</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin Glargine 2.0 u/kg body wt SC</intervention_name>
    <arm_group_label>Placebo then Insulin Glargine</arm_group_label>
    <other_name>Lantus</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  12 adults (males or females) with type 2 diabetes for at least six (6) months. May be
             using oral agents (SUs, metformin, acarbose or glitinides) with or without insulin.

          -  HgbA1c 7 -12%

          -  Age 18-70 years

          -  BMI 27-40 kg/mÂ²

        Exclusion Criteria:

          -  Any past or present clinically relevant abnormality, medical condition, or
             circumstance making the subject unsuitable for participation in the study

          -  Evidence of hepatic, renal or cardiac failure

          -  Abnormal results following screening tests

          -  Pregnant or lactating females or females of childbearing potential who are unwilling
             to abstain from sexual intercourse or use reliable, medically accepted methods of
             contraception

          -  Currently using TZDs

          -  History of alcoholism or drug abuse within 12 months of the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephen N. Davis, MD, FRCP</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vanderbilt University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Vanderbilt University</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 13, 2007</study_first_submitted>
  <study_first_submitted_qc>December 13, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 17, 2007</study_first_posted>
  <results_first_submitted>December 18, 2014</results_first_submitted>
  <results_first_submitted_qc>July 2, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 3, 2015</results_first_posted>
  <last_update_submitted>March 17, 2017</last_update_submitted>
  <last_update_submitted_qc>March 17, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 17, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vanderbilt University Medical Center</investigator_affiliation>
    <investigator_full_name>Steve Davis</investigator_full_name>
    <investigator_title>Chairman of Medicine, University of Maryland, Baltimore</investigator_title>
  </responsible_party>
  <keyword>Type 2 diabetes</keyword>
  <keyword>Insulin Glargine</keyword>
  <keyword>Endogenous Glucose Production</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin Glargine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>12 individuals will be their own controls completing 5 separate 24 hour protocol studies. If a participant does not complete all protocols, another person will be recruited to complete the protocols until there are 12 completed studies in each arm/group.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>1 All Interventions</title>
          <description>Other: 1--All interventions
All participant will be given all 5 interventions in the same order
Placebo, then 0.5 units of Glargine/kg body weight, then 1.0 units of Glargine/kg body weight, then 1.5 units of Glargine/kg body weight, then 2.0 units of Glargine/kg body weight,</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completed Placebo</title>
              <participants_list>
                <participants group_id="P1" count="12">12 original participants started the trial.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completed 0.5</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completed 1.0</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completed 1.5</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completed 2.0</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Could not place IV lines.</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>scheduling conflicts</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>One participant may have received more than one intervention.</population>
      <group_list>
        <group group_id="B1">
          <title>1--All Interventions</title>
          <description>Arm: Other: 1--All interventions
All participant will be given all 5 interventions in the same order
Placebo, then 0.5 units of Glargine/kg body weight, then 1.0 units of Glargine/kg body weight, then 1.5 units of Glargine/kg body weight, then 2.0 units of Glargine/kg body weight,</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Maximum Glucose Infusion Rate</title>
        <description>measuring the changes in glucose infusion rate during the 24 hour experimental period.</description>
        <time_frame>24 hours</time_frame>
        <population>12 participants in each arm</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Maximum glucose infusion rate</description>
          </group>
          <group group_id="O2">
            <title>0.5 Units of Glargine/kg</title>
            <description>maximum glucose infusion rate</description>
          </group>
          <group group_id="O3">
            <title>1.0 Units of Glargine/kg</title>
            <description>maximum glucose infusion rate</description>
          </group>
          <group group_id="O4">
            <title>1.5 Units of Glargine/kg</title>
            <description>maximum glucose infusion rate</description>
          </group>
          <group group_id="O5">
            <title>2.0 Units of Glargine/kg</title>
            <description>maximum glucose infusion rate</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Glucose Infusion Rate</title>
          <description>measuring the changes in glucose infusion rate during the 24 hour experimental period.</description>
          <population>12 participants in each arm</population>
          <units>umol/kg/min</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="12"/>
                <count group_id="O5" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" spread="0.3"/>
                    <measurement group_id="O2" value="2.6" spread="0.9"/>
                    <measurement group_id="O3" value="5.5" spread="1.5"/>
                    <measurement group_id="O4" value="6.8" spread="2.0"/>
                    <measurement group_id="O5" value="9.5" spread="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>2 years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Placebo
Insulin Glargine: administering single, differing dose of insulin glargine over a 24 hour period every 8 weeks times five</description>
        </group>
        <group group_id="E2">
          <title>0.5 Units of Glargine/kg Body Weight</title>
          <description>0.5 units of Glargine/kg body weight
Insulin Glargine: administering single, differing dose of insulin glargine over a 24 hour period every 8 weeks times five</description>
        </group>
        <group group_id="E3">
          <title>1 Unit of Glargine/kg Body Weight</title>
          <description>1 unit of glargine/kg body weight
Insulin Glargine: administering single, differing dose of insulin glargine over a 24 hour period every 8 weeks times five</description>
        </group>
        <group group_id="E4">
          <title>1.5 Units of Glargine/kg Body Weight</title>
          <description>1.5 units of glargine/kg body weight
Insulin Glargine: administering single, differing dose of insulin glargine over a 24 hour period every 8 weeks times five</description>
        </group>
        <group group_id="E5">
          <title>2.0 Units of Glargine/kg Body Weight</title>
          <description>2.0 units of glargine/kg body weight
Insulin Glargine: administering single, differing dose of insulin glargine over a 24 hour period every 8 weeks times five</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Stephen N. Davis</name_or_title>
      <organization>University of Maryland, Baltimore</organization>
      <phone>4103282488</phone>
      <email>sdavis@medicine.umaryland.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

